Hello,
In this paper "Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269491/ The antibiotic rifampicin was used in conjunction with a CD20-specific monoclonal antibody tositumomab (B1) (similar to Rituximab)
They found that ".....rifampicin, an inducer of P-glycoprotein, improved the activity of this transmembrane efflux pump, normalized the quantity of sphingomyelin within the membrane, and thereby restored the efficacy of the B1 monoclonal antibody in the formerly B1-resistant cases of chronic lymphocytic leukemia."
Has rifampicin been used by any CFS patients receiving rituximab to potentially aid response/increase efficacy?
Thanks,
JB
In this paper "Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269491/ The antibiotic rifampicin was used in conjunction with a CD20-specific monoclonal antibody tositumomab (B1) (similar to Rituximab)
They found that ".....rifampicin, an inducer of P-glycoprotein, improved the activity of this transmembrane efflux pump, normalized the quantity of sphingomyelin within the membrane, and thereby restored the efficacy of the B1 monoclonal antibody in the formerly B1-resistant cases of chronic lymphocytic leukemia."
Has rifampicin been used by any CFS patients receiving rituximab to potentially aid response/increase efficacy?
Thanks,
JB